[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/pages/docs/Benef/index.md) >> Individual ID:PBN__Benef_217 

# __Tracking antimicrobial usage__

## Articles mentionning this Benefit

* [Future perspectives of wastewater-based epidemiology: Monitoring infectious disease spread and resistance to the community level](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_48.md)

## Category to which it belongs

* [Synonym: proactive surveillance and response to disease transmission, prevention, and control.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_2.md)

## Description of actual returns pertaining to this benefit

* [Private investors investing in this mitigation measure could benefit from improved asset value by supporting the development of targeted antimicrobial therapies and reducing the misuse of antimicrobials, leading to improved patient outcomes and decreased healthcare costs.](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_224.md)

## Name of the Benefit

Allows for the monitoring of antimicrobial usage at a community-wide level to identify trends and provide accurate data on consumption patterns

## Risks which can benefit from this action

* [Wastewater-based epidemiology](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_202.md)

## Stakeholders benefitting from this Benefit

* [Healthcare providers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_121.md)
* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

